Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

Journal of Diabetes Investigation

Volumn 7, Issue 6, 2016, Pages 915-918

  Okamoto, Masahide ^a   Okamoto, Mitsuhiro ^a   Gotoh, Koro ^a   Masaki, Takayuki ^a   Ozeki, Yoshinori ^a   Ando, Hisae ^a   Anai, Manabu ^a   Sato, Asami ^a   Yoshida, Yuichi ^a   Ueda, So ^a   Kakuma, Tetsuya ^a   Shibata, Hirotaka ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Anti programmed cell death 1 antibodies; Fulminant type 1 diabetes; Nivolumab

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HLA ANTIGEN; INSULIN; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CASE REPORT; CHRONIC PANCREATITIS; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HAPLOTYPE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; JAPANESE (PEOPLE); KETONURIA; LIMIT OF DETECTION; MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; CHEMICALLY INDUCED; IMMUNOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84973294736     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12531     Document Type: Article

References (10)

1. Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma. Drugs 2014; 11: 1233–1239.
2. Mellati M, Eaton KD, Brooks-Worrell BM, et al. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care 2015; 9: e137–138.
3. Martin-Liberal J, Furness AJ, Joshi K, et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015; 6: 765–767.
4. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 4: e55–57.
5. Gaudy C, Clévy C, Monestier S, et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015; 11: e182–183.
6. Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000; 5: 301–307.
7. Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009; 12: 2513–2521.
8. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 1: 63–69.
9. Fujisawa R, Haseda F, Tsutsumi C, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4 + T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 2015; 3: 452–457.
10. Perri V, Russo B, Crinò A, et al. Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int J Mol Sci 2015; 9: 22584–22605.